Another FDA 483 highlighting critical data integrity failures at a sterile manufacturing site in India.

A recent U.S. Food and Drug Administration 483 inspection at Maiva Pharma Pvt. Ltd. (Hosur, Tamil Nadu, India) identified serious deficiencies in the control of original CGMP manufacturing records.

Key observations include:
🔷Original CGMP records (environmental monitoring data, leak test reports, weighing printouts, fill volume records, and dispensing logs) were discarded in scrap areas instead of being retained within controlled systems
Critical batch documentation was found:
🔸 torn, strike-marked, or disposed of without reconciliation
🔸 not marked as copies or voided through approved procedures
Aseptic intervention activities (e.g., material transfers, sanitization steps, equipment handling) were:
🔸 recorded on informal media
🔸 not captured contemporaneously in official batch records
Measurement results outside established limits were:
🔸 discarded rather than investigated
Weighing and dispensing records for raw materials and intermediates were:
🔸 not reconciled or retained under GMP controls
In combination, these findings demonstrate a failure to maintain and control original manufacturing records. Original raw data printouts generated in manufacturing areas are not subject to adequate controls, reconciliation, or retention, allowing for uncontrolled disposal of CGMP documentation with no Quality Unit oversight. Additionally, documentation of aseptic interventions is not being recorded contemporaneously, as required to ensure reliability and integrity of data.
👉 Broader Reflection
Data Integrity continues to be a major focus area for the U.S. Food and Drug Administration, and such findings repeatedly point to:
🔸 Ineffective internal audit systems
🔸 Weak management oversight and Quality Unit governance
Organizations should critically evaluate whether:
🔸 Internal audits are truly independent
🔸 Risks are being objectively identified
There is a growing need to:
🔸 Move beyond reliance on ineffective internal audits
🔸 Consider independent third-party audits to eliminate bias and organizational blind spots (e.g., Dunning–Kruger effect)
Failure to act early often leads to:
🔸 Escalation to Warning Letters
🔸 Product recalls
🔸 Significant investment in remediation and external FDA consultants